AMPH Q2 2022 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$123M+21.4% YoY

Gross Profit

$63M51.3% margin

Operating Income

$25M20.1% margin

Net Income

$17M14.0% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$724M

Total Liabilities

$224M

Stockholders' Equity

$499M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$123M	$102M	+21.4%
Gross Profit	$63M	$47M	+33.7%
Operating Income	$25M	$11M	+135.1%
Net Income	$17M	$8M	+123.3%

Revenue Segments

Research and development services

$700,000100%

Geographic Segments

UNITED STATES

$121M98%

FRANCE

$2M2%

CHINA

$766,0001%